Logo

Ibex & Medipath Entered into a Multi-Tissue Expansion of AI for Cancer in France

Share this

Ibex & Medipath Entered into a Multi-Tissue Expansion of AI for Cancer in France

Shots:

  • The companies collaborated to expand the deployment of AI to other Medipath network labs. The implementation will help Medipath pathologists with increased diagnostic accuracy & efficiency and includes new AI-powered capabilities for diagnosing a variety of tissue types
  • Ibex's solutions will be made available by Medipath to all sites in France. The Galen platform will be used by Medipath pathologists to assist in decision-making during the first diagnosis of breast, prostate, and stomach biopsies
  • The Galen platform helps to improve the accuracy of cancer diagnosis, reduce the turnaround time, boost productivity & improve the user experience for pathologists. Galen showed good outcomes in multiple clinical studies on multiple tissue types & diagnostic workflows

Ref: PR Newswire | Image: Ibex

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions